Amir Faridmoayer, Dominique Sirena, Veronica Gambillara Fonck
Company Description
Biotech startup GlycoEra pioneers a new class of therapies called extracellular protein degraders. By selectively targeting proteins outside cells, their technology offers a novel therapeutic modality, especially for hard-to-treat autoimmune and inflammatory conditions.
Market
Therapeutics
Location
Switzerland
Coinvestors
Novo Holdings, Catalio Capital Management, LifeArc Ventures, QIA, Sofinnova Partners, 5AM Ventures, Roche Ventures, Bristol Myers Squibb, Agent Capital, MP Healthcare Venture Management, Sixty Degree Capital